NCT07388667CompletedPhase 1
A Clinical Study of MK-4082 in Healthy Overweight Participants (MK-4082-002)
A Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MK-4082 in Healthy Overweight/Obese Participants
Source: ClinicalTrials.gov · Last updated 23 Sept 2026
Brief summary (registry, in English)
Researchers are looking for new weight loss medicines for people with higher body weight. The study medicine, MK-4082, is different from similar weight loss medicines because people take it as a pill instead of an injection. Before giving a study medicine to people with a health condition, researchers first do studies to find a safe dose level (amount) of the study medicine that can be used in future studies. The goals of this study are to learn about: * The safety of MK-4082 and if people tolerate it * What happens to different MK-4082 dose levels in a person's body over time
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 122 (actual)
- First submitted
- 29 Jan 2026
- Start date
- 4 Mar 2026
- Primary completion date
- 1 Sept 2026
- Lead sponsor
- Merck Sharp & Dohme LLC
- Diseases
- Obesity
- NCT number
- NCT07388667
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 122
- From 4 Mar 2026 to the primary completion date, 1 Sept 2026
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- has a history of previous surgical treatment for obesity (bariatric surgery, gastric banding, etc.) or any other gastrointestinal (GI) surgery that may induce malabsorption, history of bowel resection \>20 cm, any malabsorption disorder, severe gastroparesis, or any GI procedure for weight loss (including LAP-BAND®), as well as clinically significant GI disorders (eg, peptic ulcers, severe gastroesophageal reflux disease)
Other illness
- has an individual or family history of medullary thyroid carcinoma or multiple endocrine neoplasia 2
Other
- The main exclusion criteria include but are not limited to the following:
Who the study is looking for
- The main inclusion criteria include but are not limited to the following:
- Is in good health
- Has body mass index (BMI) between 25 and 40 kg/m\^2, inclusive. Participants must weigh at least 60 kg
Age in the registry: 18 years to 60 years · Sex: All · Accepts healthy volunteers
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| ProSciento Inc. ( Site 0002) Coordinator of this site? Confirm its status | Chula Vista | United States | Unknown status |
| Hassman Research Institute Marlton Site ( Site 0006) Coordinator of this site? Confirm its status | Marlton | United States | Unknown status |
| QPS-MRA, LLC ( Site 0003) Coordinator of this site? Confirm its status | South Miami | United States | Unknown status |
| Bio-Kinetic Clinical Applications, LLD dba QPS-MO ( Site 0004) Coordinator of this site? Confirm its status | Springfield | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.